Heparin/argatrobanHeparin-induced thrombocytopenia and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1883卷 / 1期

关键词：

D O I：

10.1007/s40278-021-06145-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：190 / 190

相关论文

共 50 条

[31] Multiple drugsOff label use and heparin-induced thrombocytopenia: case report
Reactions Weekly, 2020, 1825 (1) : 161 - 161
[32] Multiple drugsVarious toxicities, off-label use and no response to off-label therapy: case report
Reactions Weekly, 2021, 1861 (1) : 232 - 232
[33] Efficacy and Safety of Off-Label Use of Fondaparinux in the Management of Heparin-Induced Thrombocytopenia With Thrombosis in an Elderly Woman
Leporini, Christian
Rende, Antonio
Sorrentino, Alfonso
Rizzica, Elvira
Russo, Emilio
Gallelli, Luca
De Sarro, Giovambattista
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (09): : 999 - 1002
[34] NivolumabFever following off-label use: case report
Reactions Weekly, 2016, 1601 (1) : 186 - 186
[35] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[36] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[37] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[38] Paclitaxel/vemurafenibMyelosuppression and off-label use: case report
Reactions Weekly, 2022, 1888 (1) : 292 - 292
[39] BevacizumabRetinal breaks and off-label use: case report
Reactions Weekly, 2022, 1924 (1) : 120 - 120
[40] Mirtazapine/pregabalinDelirium and off-label use: case report
Reactions Weekly, 2024, 2029 (1) : 384 - 384

← 1 2 3 4 5 →